Vascular Endothelial Growth Factor A

Patient enrollment is complete in two phase 3 clinical trials investigating faricimab in diabetic macular edema, according to correspondence from Genentech and Roche.

The FDA has approved Beovu for the treatment of wet age-related macular degeneration, Novartis announced in a press release.

An intravitreal dose of ADVM-022, a gene therapy designed for long-term VEGF suppression via the expression of aflibercept, resulted in no anti-VEGF rescue injections for patients with wet age-related macular degeneration, according to 24-week clinical data in the OPTIC phase 1 clinical trial.

Visual and anatomical gains made with aflibercept monotherapy for polypoidal choroidal vasculopathy were maintained long term, according to a study looking at the second-year data of the PLANET trial.

PARIS — Partnering with Fight for Sight, the European Society of Retina Specialists will award a 2 million euros grant to a research project addressing the best treatment option for submacular hemorrhage secondary to wet age-related macular degeneration.

Phase 1 study results for THR-149, Oxurion’s plasma kallikrein inhibitor, showed it to be safe and well tolerated with a rapid onset of action from the first day of treatment in patients with diabetic macular edema, according to a press release.

THR-317, a humanized antibody against placental growth factor, combined with ranibizumab showed no improvement in mean best corrected visual acuity compared with ranibizumab monotherapy in a phase 2a study, Oxurion announced in a press release.

Here are some of the recent top stories on Healio.com/OSN:

CHICAGO — In a large retrospective review of real-world rates of endophthalmitis after intravitreal anti-VEGF and steroid injections, rates were low and similar to reported rates in clinical trials, according to a speaker here.

The European Medicines Agency has validated the marketing authorization application for abicipar, Molecular Partners announced.